DIRS.INFO The most relevant business & tech news

☆ Common food dye can make skin transparent in mice, study finds
▼ + stars: | 2024-09-05 | by ( Katie Hunt | ) edition.cnn.com time to read: +8 min

“But when we put them together, we were able to achieve transparency of the mouse skin.”Once the dye had completely diffused into the skin, the skin became transparent. In mice, the researchers were able to observe blood vessels directly in the surface of the brain through the transparent skin of the skull. Guosong Hong/Stanford UniversityThe transparent areas take on an orangish color, Ou said, similar to that of the food dye. 5 dye, a common food coloring, was used at a low concentration in the study, and its effects were easily undone, according to the researchers. “However, a partially transparent (mouse) will already enable numerous research opportunities to answer questions relating to development, regeneration, as well as aging.”

Persons: Wells, ”, Zihao Ou, ” Ou, “, Hong, Ou, Guosong Hong, Stanford University Christopher Rowlands, Rowlands, wasn’t, Jon Gorecki, Gorecki, tartrazine Organizations: CNN, University of Texas, NSF, Stanford University in, Stanford University, US Food and Drug Administration, California, Environmental Health, Stanford, Imperial College London Locations: H.G, Dallas, Stanford University in California, California, bioengineering, Ou

If approved, it would have been the first new treatment for PTSD in more than two decades. Lykos Therapeutics had asked the FDA to approve the drug as part of a treatment regimen, given alongside talk therapy. Lykos Therapeutics had asked the FDA to approve the drug as part of a treatment regimen, given alongside talk therapy. Lykos added that the agency expressed concerns similar to those raised during the advisory committee meeting in June. Davis Institute for Psychedelics and Neurotherapeutics, said he doesn’t think the FDA decision will hinder the development of psychedelics for mental health disorders, including PTSD.

Persons: “, ”, Holly Fernandez Lynch, Lykos, Amy Emerson, Sarah Silbiger, David Olson, Olson, ” Olson, Brian Barnett, ” Barnett, Joe Biden, Biden, Robert Califf, ” Lynch, psychedelics, David Rind Organizations: Drug Administration, Therapeutics, FDA, Lykos Therapeutics, University of Pennsylvania, Davis Institute for Psychedelics, Cleveland Clinic, Clinical Locations: U.S, White Oak, Md, Ohio

☆ Antiaging enthusiasts are getting $16,500 injections to make their knees young again
▼ + stars: | 2024-08-09 | by ( ) www.businessinsider.com time to read: +11 min

For now, here's what we know — and what we don't know — about stem-cell therapy for knees. Bryan Johnson flew to the Bahamas to get MSC stem cells injected into his knees, hips, and shoulders — for about $16,500 per joint. Plus, even Sampson warns that young donor stem cells should not be seen as a quick fix or a panacea. Done with proper medical oversight, some studies have found no adverse effects from stem-cell treatments for various conditions. Botched stem-cell treatments can cause infection, blindness, and excessive cell growth, which can trigger the formation of tumors.

Persons: —, Bryan Johnson, Johnson, hasn't, Josh DeAngelis, Rasul Chaudhry, Chaudhry, Steven Sampson, Chaundhry, Sampson, Peyton Manning, Patrick Smith, George Kittle, Hulk Hogan, TJ Dillashaw, Rafael Nadal, Jack Nicklaus, I've, it's, Paul Knoepfler, he's, It's, Mattias Bernow, we'll, Knoepfler Organizations: Service, Business, MSC, Oakland University, NFL, FDA, UFC, ESPN, CNN, UC Davis School of Medicine Locations: Bahamas, Panama

☆ Eli Lilly's second quarter eases Zepbound pricing fears and suggests it's making headway in weight loss race
▼ + stars: | 2024-08-08 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +5 min

Lilly's shares are up more than 7% on the news. LLY YTD mountain Eli Lilly shares year to date. The first followed positive reports from rivals that showed they were making progress in developing their own weight loss drugs . However, sales rose 59% for Mounjaro quarter over quarter and were up 140% for Zepbound as Lilly saw better pricing. Meanwhile, analysts see several events on the horizon that could further boost Lilly's shares in coming months.

Persons: Eli Lilly, Bansal, Lilly, Carter Gould, Lilly's headwinds, Novo's, Wells Fargo's Bansal, Evan David Seigerman, Chris Schott, Schott, Lilly's Organizations: Novo Nordisk, Wells, Barclays, Nordisk, BMO Capital Markets, Food and Drug Administration Locations: Wells Fargo, Lilly's, Wednesday's

☆ Beyond Facials and Yoga: 6 Resorts With Next-Level Wellness Programs
▼ + stars: | 2024-08-02 | by ( Stephanie Rosenbloom | ) www.nytimes.com time to read: 1 min

Take part in a ritual during which a temazcalero, or guide, will lead you through breathing exercises, chants and drumming with the aim of renewing your energy, followed by time in a temazcal dome, where steam rises from hot stones. Attend a class like singing bowl therapy or meditation. Learn how to make essential oils and herbal pillows at an aromatherapy workshop. Or take a contemplative walk in the labyrinth. There’s also a fitness studio, two hilltop pools and water-themed therapies, including an ice bath, at the hotel’s Desert Springs hydrotherapy facility.

Locations: U.S, Baja California

☆ Germany’s doctors can prescribe four-week spa breaks to frazzled parents
▼ + stars: | 2024-08-01 | by ( Ulrike Lemmin-Woolfrey | ) edition.cnn.com time to read: +8 min

Those lucky parents may leave with doctor’s orders for a four-week spa break by the sea or in the mountains. Germany has around 350 designated spa towns, with many designated as UNESCO World Heritage sites. ‘I had severe sleeping problems’Focused on preventative as well as restorative care, a Kur is frequently aimed at burned-out parents. The proportion of single parents in MGW clinics is disproportionately high in relation to the overall share in society. “Together, solutions are developed that will help patients to cope with everyday life again and prevent (further) health problems,” Gerstkamp explained.

Persons: ”, They’ve, Cécile Poirot, ” Poirot, “, Müttergenesungswerk, Petra Gerstkamp, Gerstkamp, Poirot, ” Gerstkamp Organizations: CNN, UNESCO, Heritage, “ Locations: Germany, Baden, Wiesbaden, Bad, Europe, Elmshorn, Hamburg

☆ Biogen beats expectations, hikes outlook as Alzheimer's drug Leqembi and other new products gain traction
▼ + stars: | 2024-08-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Biogen on Thursday reported second-quarter earnings and revenue that topped estimates and hiked its full-year guidance, as the company's cost cuts showed progress and sales of its breakthrough Alzheimer's drug, Leqembi, and other new products beat expectations. Leqembi, which Biogen shares with Eisai, became the second drug proven to slow the progression of Alzheimer's to win approval in the U.S. last summer. That's above the $31 million analysts had expected, according to estimates compiled by StreetAccount. Tecfidera, for example, booked $252.2 million in revenue in the second quarter, which is relatively flat from the year-earlier period. Analysts had expected the once-blockbuster drug to rake in $233.3 million in revenue for the quarter, according to StreetAccount.

Persons: Biogen, StreetAccount, Leqembi, Drug Administration greenlit Skyclarys, Biogen's Organizations: Eisai, LSEG, Reata Pharmaceuticals, Drug Administration, Sage Therapeutics Locations: U.S, Europe

☆ GEHC gives reasons to look beyond temporary China woes and shares reverse higher
▼ + stars: | 2024-07-31 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

GE Healthcare on Wednesday morning reported a mixed second quarter and shares initially moved sharply lower. Organic revenue growth was 1%. We saw a continued acceleration of Vizamyl doses delivered in the U.S. in the second quarter. This is still a small contributor to sales growth but gives us optimism about its sales potential over the next few years." As a result, we're lowering our total company full-year organic revenue growth guidance."

Persons: Philips, It's, Eli Lilly, GEHC, —, Jay Saccaro, We're, Arduini, Peter Arduini, Jim Cramer's, Jim Cramer, Jim, Pavlo Gonchar Organizations: GE Healthcare, Management, Revenue, LSEG, General Electric, Philips, Siemens, Club, GE Healthcare YTD, GE Healthcare's, Care Solutions, Pharmaceutical Diagnostics, U.S, CNBC, Lightrocket, Getty Locations: China, Eisai, U.S

☆ Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
▼ + stars: | 2024-07-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +5 min

George Frey | ReutersAn older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer's disease by protecting patients' brains, according to data from a mid-stage trial released on Tuesday. Novo Nordisk sells liraglutide as a diabetes and obesity drug under the brand names Victoza and Saxenda, respectively. Alzheimer's disease often causes the brain to shrink as the illness progresses because crucial nerve cells break down and stop working properly. By 2050, the number of Alzheimer's patients is projected to rise to almost 13 million in the U.S. The ongoing EVOKE is examining semaglutide, the active ingredient in Wegovy and Ozempic, in nearly 2,000 Alzheimer's patients.

Persons: George Frey, Eli Lilly, liraglutide, Brian B, Bettencourt, Heather Snyder, Leqembi, Snyder, Dr, Paul Edison, Edison, Bobby Pugh, Bessie Pugh, Karen Pulfer Focht Organizations: Novo Nordisk Pharmaceutical, Reuters, Novo Nordisk, Imperial College London, Alzheimer's Association International Conference, Toronto Star, Getty, Alzheimer's Association, U.S, CNBC, Alzheimer's, Novo Nordisk's, Ave Locations: Provo , Utah, Danish, Philadelphia, Biogen, Novo, Bartlett , Tennessee, U.S

☆ Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
▼ + stars: | 2024-07-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

The newly FDA approved Alzheimer's treatment Leqembi is prepared at Abington Neurological Associates in Abington, PA., on Tuesday, November 7, 2023. The breakthrough Alzheimer's drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term, according to new data released Tuesday by Japanese drugmaker Eisai. The study results on Leqembi, which Eisai shares with Biogen , also found that a patient's Alzheimer's disease worsens after they stop treatment. The results are a first glimpse at what Alzheimer's patients' future could look like on therapies such as Leqembi, which is currently taken twice a month through an infusion. By 2050, the number of Alzheimer's patients is projected to rise to almost 13 million in the U.S.

Persons: Lynn Kramer, Leqembi, Eisai, Kramer Organizations: FDA, Abington Neurological Associates, Biogen, CNBC, Alzheimer's Association International Conference, Alzheimer's Association Locations: Abington, Abington , PA, U.S, Philadelphia

☆ These drugmakers are catching up to Eli Lilly and Novo Nordisk in weight loss treatments
▼ + stars: | 2024-07-28 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +6 min

With billions at stake, that's pretty much been a guarantee facing the current market leaders, Eli Lilly and Novo Nordisk , from the start. Their updates are likely to be joined by others in the coming months even as today's incumbents develop their own next-generation weight loss treatments. Other analysts have also grown more optimistic about the future of weight loss treatments. Orforglipron, a once-a-day oral GLP-1 drug that Lilly is working on, had shown a 3% weight loss at 4 weeks. The company is also exploring whether the weight loss treatment could be given only once a month.

Persons: Eli Lilly, drugmakers Roche, Lilly, Denmark's, Trung Huynh, Huynh, Rajesh Kumar, Kumar, Novo, Roche, Roche ADRs, Justin Zelin, Zelin, Viking's, HSBC's Kumar, Novo aren't, —, Nick Wells Organizations: Novo Nordisk, Viking Therapeutics, UBS, HSBC Global Research, Carmot Therapeutics, Food and Drug Administration, Viking, European Association for, Diabetes, Pfizer, Amgen, Therapeutics Locations: Swiss, Novo, San Antonio, Spain

☆ Pfizer's gene therapy for rare genetic bleeding disorder succeeds in late-stage trial
▼ + stars: | 2024-07-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Pfizer on Wednesday said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval. Without enough of that protein, the blood cannot clot properly, increasing the risk of spontaneous bleeding and severe bleeding after surgery. Pfizer said its one-time treatment significantly cut the number of annual bleeding episodes in patients with moderately severe to severe hemophilia A after 15 months. If approved, Pfizer's therapy will compete with BioMarin Pharmaceutical 's one-time treatment Roctavian. BioMarin is reportedly considering whether to divest its hemophilia A therapy, which costs $2.9 million.

Persons: Andrew Leavitt, Pfizer Organizations: Pfizer, Sangamo Therapeutics, BioMarin Locations: U.S

☆ New Hampshire Bans Gender-Transition Surgery for Minors
▼ + stars: | 2024-07-19 | by ( Adeel Hassan | ) www.nytimes.com time to read: +2 min

The NewsNew Hampshire will ban gender-transition surgeries for minors after Gov. Chris Sununu signed a bill on Friday that bars health professionals from performing the procedures. The new law also threatens disciplinary action for doctors who refer minors to other providers for such services. About two dozen other states have passed laws that bar transgender minors from receiving gender-transition care. Before Friday, Mr. Sununu had taken a relatively mixed stance on gender-identity issues and L.G.B.T.Q.

Persons: Chris Sununu, Mr, Sununu, ” Mr, “, Courtney Tanner Organizations: New, Gov, Republican, Republican Party, Dartmouth Health Locations: New Hampshire

☆ Popular weight loss and diabetes drugs linked to increased risk of rare form of blindness
▼ + stars: | 2024-07-03 | by ( Deidre Mcphillips | ) edition.cnn.com time to read: +6 min

CNN —People who take Ozempic or Wegovy may have a higher risk of developing a rare form of blindness, a new study suggests. The condition is relatively rare — up to 10 out of 100,000 people in the general population may experience it — but the doctors noted three cases in one week, and each of those patients was taking semaglutide medications. The risk was found to be greatest within the first year of receiving a prescription for semaglutide. Semaglutide prescriptions have soared in the US, which could raise the number of people at risk for a potential side effect. But the large number of people who are taking semaglutide should raise confidence that the absolute risk of developing NAION as a result is rare.

Persons: ”, Joseph Rizzo, ” Susan Mollan, Disha, Dr, Sanjay Gupta, Chanapa, Andrew Lee, ” Narang Organizations: CNN —, Mass, Novo Nordisk, CNN, Harvard Medical School, ”, University Hospitals Birmingham, Endeavor Health, CNN Health, US Food and Drug Administration, FDA, American Academy of Ophthalmology, Houston Methodist Hospital Locations: Chicago

☆ In new criteria for Alzheimer’s, some see much-needed progress while others fear profit may be driving ‘diagnostic creep’
▼ + stars: | 2024-07-01 | by ( Brenda Goodman | ) edition.cnn.com time to read: +12 min

CNN —With another pricey Alzheimer’s disease treatment expected to receive an approval decision soon, the nonprofit Alzheimer’s Association has published the final version of its new diagnostic criteria for the disease. Together with another protein, tau, which makes fibrous tangles that block the communication of nerve cells, they are considered a hallmark of Alzheimer’s disease. “There’s no evidence for it,” said Dr. George Perry, a neurobiologist and editor of the Journal of Alzheimer’s Disease. Two members of the panel were employees of the Alzheimer’s Association, which also takes funding from pharmaceutical companies. Widera says he hopes that in the next round of guidelines, the Alzheimer’s Association will consider the risks involved.

Persons: There’s, –, donanemab, “, ”, George Perry, Adriane Fugh, Berman, haven’t, Maria C, Carrillo, Alzheimer’s, It’s, Eric Widera, Widera, it’s, Aduhelm, Karl Herrup, Clifford Jack, ” Jack, “ It’s, Niles Franz, ” Franz, Dr, Sanjay Gupta, Franz, ” Widera Organizations: CNN, Alzheimer’s Association, Food and Drug Administration, FDA, Georgetown University, University of California San, American Geriatrics Society, Abbott Labs, University of Pittsburgh School of Medicine, Mayo Clinic, Nature Medicine, federal National Institute, Aging, Alzheimer’s Association International, National Institute, National Institutes of Health, NIA, Alzheimer’s, National Academy of Medicine, CNN Health, Association Locations: University of California San Francisco

☆ Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline
▼ + stars: | 2024-06-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +19 min

But other current employees are dissatisfied with where the strategy shift has left them. In January 2023, Pfizer forecast a steep drop in annual revenue, to between $67 billion and $71 billion. Pfizer's 2023 revenue ultimately came in at $58.5 billion, including $11.22 billion from its Covid vaccine and $1.28 billion from Paxlovid. Faith in executive leadership also plunged among some workers, according to most of the current and former employees who spoke with CNBC. Some current workers said that hasn't appeared to change after the town hall on May 2.

Persons: Albert Bourla, Wall, they're, Bourla, I'm, drugmaker Seagen, Irfan Khan, hasn't, Pfizer, renegotiating, John Thys, Payal Sahni Becher, Becher, Kena, Mike McDermott, Bourla's Organizations: Corbis, Getty, Pfizer, Wall, CNBC, Los Angeles Times, Moderna, Centers for Disease Control, U.S ., GSK, Bristol Myers Squibb, Pfizer wasn't, . Biotech, Companies, Biotech, BioNtech, Reuters, Human, View Press, Global, APEC, Summit, Tech, Google Locations: U.S, Covid, Eagle Rock , California, Durham , North Carolina, Puurs, Belgium, New York City, Peapack , New Jersey, Kena

☆ Texas Supreme Court upholds state’s ban on gender-affirming care for minors
▼ + stars: | 2024-06-28 | by ( Andy Rose | Kaanita Iyer | ) edition.cnn.com time to read: +3 min

CNN —The Texas Supreme Court ruled Friday to allow the state’s ban on nearly all gender-affirming care for minors to remain in effect. The law bars Texas health care providers from providing gender transition surgeries, puberty-blocking medication or hormone therapies to those under 18, although exceptions are provided for intersex patients. Texas’ ban is similar to restrictions in nationwide as GOP-led states have moved to curb gender-affirming care for minors, expressing concerns over the long-term effects of such treatment — though major medical associations have deemed it clinically appropriate. More than 20 states have enacted restrictions on gender-affirming care for minors. The Biden administration directly challenged Tennessee’s ban on gender-affirming care for minors, and the US Supreme Court announced this week that it will hear the appeal, which will determine whether states can restrict such care.

Persons: “, ”, ” Karen Loewy, Greg Abbott’s, ” “, Andrew Mahaleris, Abbott, Biden, CNN’s Jack Forrest, Chris Boyette Organizations: CNN, The, The Texas Supreme, Republican, ”, Texas, GOP, Lambda, Lambda Legal, Texas GOP Gov, Texas Legislature, “, US Supreme Locations: The Texas, Texas

☆ Novo Nordisk to build $4.1 billion North Carolina facility to boost output of Wegovy, Ozempic
▼ + stars: | 2024-06-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Novo Nordisk on Monday said it will spend $4.1 billion to build a new manufacturing plant in Clayton, North Carolina, in a bid to boost the supply of its blockbuster weight loss drug Wegovy, diabetes treatment Ozempic and other injectable therapies. The company said it plans to invest $6.8 billion in production this year, up from roughly $4 billion last year. Construction of the 1.4 million-square-foot facility has begun and is expected to be completed between 2027 and 2029, Novo Nordisk said. Twelve other production sites are located in Denmark, France, China, Japan, Algeria, Brazil, Iran and Russia, according to a Novo Nordisk spokesperson. Around 35,000 U.S. patients on average start Wegovy each week today, up from roughly 27,000 in May, a Novo Nordisk spokesperson said in a statement.

Persons: Doug Langa, Clayton —, Langa, Eli Lilly Organizations: Novo Nordisk, Danish, Novo Nordisk's, Drug Administration Locations: Clayton , North Carolina, U.S, Novo, North Carolina, Clayton, Durham , North Carolina, West Lebanon , New Hampshire, Denmark, France, China, Japan, Algeria, Brazil, Iran, Russia

☆ SIRO, One Za’abeel: Dubai’s ‘first fitness hotel’ is taking wellness tech to the next level
▼ + stars: | 2024-06-21 | by ( Rebecca Cairns | ) edition.cnn.com time to read: +8 min

“The industry is evolving,” says Desmond Cawley, hotel manager at SIRO, One Za’abeel. This kind of light therapy treatment has its roots in NASA’s experimentation with red light therapy in the 1990s to boost plant growth in space and help heal wounds in astronauts. Rebecca Cairns/CNNEven at SIRO, with all its cutting-edge tech, Cawley has observed a surge of interest in mindfulness activities like meditation. Of course, at SIRO, there’s even a high-tech alternative to this: “vibroacoustic therapy,” the sci-fi equivalent of a gong bath. Tech to help you disconnect might seem excessive, but for SIRO, the integration of health data is the future of wellness, providing guests with a data-driven, personalized wellness program.

Persons: ”, Desmond Cawley, SIRO, Dubai’s, Adam Peaty, Ramla Ali, Cawley, it’s, Rebecca Cairns, Boka, “, Beth McGroarty, that’s, ” McGroarty, SIRO isn’t, McGroarty, —, there’s Organizations: CNN, AC Milan football, Kerzner, Global Wellness Institute, bros, Equinox Locations: Dubai, Montenegro, New York City, SIRO, Cryotherapy

☆ Weight loss drug contender Zealand Pharma jumps 23% on trial results
▼ + stars: | 2024-06-21 | by ( Jenni Reid | ) www.cnbc.com time to read: +1 min

Vials on the Wegovy line at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on Friday, March 8, 2024. LONDON — Shares of Denmark's Zealand Pharma popped nearly 23% in Friday morning deals, notching a record high after an early-stage study of its weight loss drug challenger produced positive results. Petrelintide was "judged to be safe and well tolerated at all dose levels" and the results provided "robust support" for its potential as an alternative to GLP-1 receptor agonist-based therapies for weight management, Zealand Pharma said in a release. GLP-1RA-based treatments include Ozempic, the diabetes drug produced by fellow Danish pharmaceutical firm Novo Nordisk , which has exploded in popularity globally for its weight-loss effects. Soaring demand for Ozempic and obesity drug Wegovy have propelled Novo Nordisk to become Europe's most valuable company.

Persons: Petrelintide Organizations: Novo Nordisk, Denmark's Zealand Pharma, Zealand Pharma Locations: Hillerod, Denmark, Danish

☆ 6 types of depression identified in Stanford study
▼ + stars: | 2024-06-20 | by ( Kristen Rogers | ) edition.cnn.com time to read: +11 min

Some 30% to 40% of people with depression do not experience symptom improvement after trying one treatment, according to the study. And about 30% of people diagnosed with depression go on to experience treatment-resistant depression when the disorder doesn’t improve after multiple treatment attempts. Mapping depression in the brainThe authors used data from 801 adult participants who were previously diagnosed with depression or anxiety, and 137 healthy control group participants. The grant supports a five-year project involving 4,500 participants, which is centered on the development of a better diagnosis and treatment tool for depression biotypes. This method isn’t intended to replace or be the primary choice for assessments of individual cases of depression, Williams said.

Persons: biotypes, ”, Leanne Williams, Vincent V.C, Woo, Williams, Anhedonia, Jun Ma, Ma, Beth, George Vitoux, “, Richard Keefe, wasn’t, Keefe, Jonathan Alpert, Dorothy, Marty Silverman, Alpert, ” Keefe, you’re Organizations: Lifeline, CNN, Nature Medicine, Psychiatry, Behavioral Sciences, Stanford University School of Medicine, Stanford Center, Precision Mental Health, Wellness, Medicine, University of Illinois, Duke University Medical Center, Montefiore Medical, Albert Einstein College of Medicine, Psychiatric Association’s Council, Research, National Institute of Mental Health, National Institutes, Health’s, Mental Health Initiative Locations: California, United States, University of Illinois Chicago, North Carolina, New York City, Stanford

☆ This little-known biotech stock is primed to surge nearly 50%, Canaccord says
▼ + stars: | 2024-06-20 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +1 min

Positive data from Intra-Cellular Therapies ' latest study could herald further success for the biotechnology stock, according to Canaccord Genuity. The updated forecast implies that shares of Intra-Cellular Therapies could soar nearly 50% from their Tuesday close at $75.48. "We believe the solidity of the Phase 3 data means an approval for luma in MDD is more of a when, not if." Shares of Intra-Cellular Therapies have risen less than 4% this year. But the analyst believes the stock has been "somewhat constrained" due to investors' overly cautious nature with luma's potential patent runway, he wrote.

Persons: Canaccord, Sumant Kulkarni, Kulkarni, —, Fred Imbert Organizations: Therapies, Cellular Locations: MDD

☆ Having an only child means we have more time and resources for her. But it doesn't make her spoiled.
▼ + stars: | 2024-06-17 | by ( Sara Rowe Mount | ) www.businessinsider.com time to read: +4 min

As the parent of an only child, I often field questions like, "Does she have any siblings?" I considered having more kids before I got pregnantAt one point, I considered having more than one child. Unsurprisingly, my husband was fully on board with never, ever having to go through it all again. Being a mother is still incredibly challenging for meAs an only child my daughter does get more by default. AdvertisementMy daughter's developmental delays and autism mean she needs more of my physical and emotional reserves than a neurotypical child.

Persons: brats, I've, I'm Organizations: Service Locations: Colorado

☆ Brain science start-up Neuroelectrics uses electricity and a headcap to reduce seizures in patients with epilepsy. Now it needs FDA approval
▼ + stars: | 2024-06-14 | by ( Cristy Garratt Maria Gomez De Sicart | Cristy Garratt | Https | ) www.cnbc.com time to read: +1 min

High up in the hills of Barcelona, brain science start-up Neuroelectrics is developing therapies that it says will improve the lives of people living with brain disease. Its main product is a headcap, which monitors the brain's electrical activity and stimulates regions of the brain with mild electrical currents. Co-founder and CEO Ana Maiques believes it will significantly improve the lives of people suffering with epilepsy. In addition to epilepsy, Maiques and her team are optimistic that the headgear can also be used to treat depression and Alzheimer's. So, when you have epilepsy, you have an electrical discharge in one area of your brain, so they can really target and help them," said Roser Sanchez-Todo, R&D director for Neuroelectrics' brain modelling department.

Persons: Ana Maiques, Maiques, Roser Sanchez, Neuroelectrics Organizations: CNBC Tech, U.S . Food, Drug Administration Locations: Barcelona

☆ Why CEO AstraZeneca believes the drugmaker can almost double revenue by 2030
▼ + stars: | 2024-06-04 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

AstraZeneca CEO Pascal Soriot explained in a Tuesday interview with CNBC's Jim Cramer why the drugmaker believes it can almost double revenue by 2030. The pharmaceutical giant also plans to release 20 new drugs by 2030, half of which will treat cancer, Soriot said. The company recently released promising results about several of its cancer drugs at the American Society of Clinical Oncology's annual meeting, including ones for lung and breast cancers. Soriot said researchers are quickly developing new and promising cancer treatments. He said new cell therapies have the potential to cure patients, and he also pointed to antibody-drug conjugates — which, unlike chemotherapy, aim to target cancer cells while sparing healthy ones.

Persons: Pascal Soriot, CNBC's Jim Cramer, we're, Soriot Organizations: AstraZeneca, American Society, Clinical, CNBC

Search resuls for: "Therapies"

25 mentions found